| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2410897 | Vaccine | 2005 | 7 Pages |
Abstract
Lumazine synthase from Brucella spp. (BLS) was evaluated as a protein carrier to improve antigen delivery of KETc1, one of the peptides of the anti-cysticercosis vaccine. KETc1 becomes antigenic, preserved its immunogenicity and its protective capacity when expressed as a recombinant chimeric protein using Brucella spp. lumazine synthase. KETc1 and BLS-KETc1 were not MHC H-2d, H-2k nor H-2b haplotype-restricted albeit KETc1 is preferentially presented in the H-2b haplotype. These findings support that BLS is a potent new delivery system for the improvement of subunit vaccines.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Edda Sciutto, Andrea Toledo, Carmen Cruz, Gabriela Rosas, Gabriela Meneses, Diego Laplagne, Natalia Ainciart, Jacquelynne Cervantes, Gladis Fragoso, Fernando A. Goldbaum,